Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

NCT00911573 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Skin Diseases
Infection

Interventions

DRUG: Tigecycline
DRUG: Clindamycin (or Vancomycin if needed)

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer